Growth Hormone and Heart Failure: Implications for Patient Stratification, Prognosis, and Precision Medicine

被引:3
|
作者
Theodorakis, Nikolaos [1 ,2 ,3 ]
Kreouzi, Magdalini [4 ]
Hitas, Christos [3 ]
Anagnostou, Dimitrios [3 ]
Nikolaou, Maria [3 ]
机构
[1] Clin Metab & Athlet Performance, NT Cardiometab, Palaio Faliro 17564, Greece
[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens 11527, Greece
[3] Sismanogleio Amalia Fleming Gen Hosp, Dept Cardiol, Melissia 15127, Greece
[4] Sismanogleio Amalia Fleming Gen Hosp, Dept Internal Med, Melissia 15127, Greece
关键词
growth hormone; insulin-like growth factor-I; heart failure; anabolic hormones; multiple hormonal deficiency syndrome; randomized controlled trials; precision medicine; LEFT-VENTRICULAR FUNCTION; HUMAN GH THERAPY; EXERCISE CAPACITY; PERFORMANCE; DEFICIENCY;
D O I
10.3390/diagnostics14242831
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart failure (HF) remains a major cause of morbidity and mortality worldwide. While standard treatments primarily target neurohormonal pathways, emerging evidence highlights the significant role of hormonal deficiencies, such as impaired growth hormone (GH) signaling, in HF progression and outcomes. GH is crucial for cardiovascular and skeletal muscle function, and its deficiency has been associated with worse prognosis. This review synthesizes recent findings from randomized controlled trials (RCTs) to explore how GH can contribute to personalized care and improve patient stratification in HF. A comprehensive literature review was conducted using PubMed up to 10 October 2024. Search terms included "growth hormone" combined with "heart failure", "HFrEF", "HFpEF", and "HFmrEF." Only placebo-controlled RCTs published in English and involving human subjects were considered. Data on study design, participant characteristics, GH dosing, and key clinical outcomes were systematically extracted and analyzed. Several trials demonstrated that GH therapy can transiently improve left ventricular ejection fraction (LVEF), exercise capacity, and reduce inflammatory markers. For example, one study has reported an increase in LVEF from 32 +/- 3.8% to 43.8 +/- 4.6% (p = 0.002), following three months of GH therapy in post-MI HF patients. However, benefits diminished after discontinuation. Additional studies have observed sustained improvements in peak oxygen consumption and LVEF over four years, with an additional trend towards hard endpoint improvement. Conversely, some studies showed no significant impact on cardiac function, highlighting heterogeneity in outcomes. As a result, GH therapy holds promise for improving cardiac and functional parameters in HF patients, but evidence remains mixed. Larger, long-term RCTs are needed to confirm its efficacy and safety. Precision medicine approaches and biomarker-driven strategies may optimize patient outcomes and guide clinical practice.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Risk Stratification Towards Precision Medicine in Heart Failure - Current Progress and Future Perspectives -
    Nagai, Toshiyuki
    Nakao, Motoki
    Anzai, Toshihisa
    CIRCULATION JOURNAL, 2021, 85 (05) : 576 - 583
  • [2] Role of growth hormone in chronic heart failure - Therapeutic implications
    Volterrani, M
    Manelli, F
    Cicoira, M
    Lorusso, R
    Giustina, A
    DRUGS, 2000, 60 (04) : 711 - 719
  • [3] Towards precision medicine in heart failure
    Chad S. Weldy
    Euan A. Ashley
    Nature Reviews Cardiology, 2021, 18 : 745 - 762
  • [4] Towards precision medicine in heart failure
    Weldy, Chad S.
    Ashley, Euan A.
    NATURE REVIEWS CARDIOLOGY, 2021, 18 (11) : 745 - 762
  • [5] Acquired growth hormone resistance in patients with chronic heart failure: Implications for therapy with growth hormone
    Anker, SD
    Volterrani, M
    Pflaum, CD
    Strasburger, CJ
    Osterziel, KJ
    Doehner, W
    Ranke, MB
    Poole-Wilson, PA
    Giustina, A
    Dietz, R
    Coats, AJS
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (02) : 443 - 452
  • [6] Growth hormone resistance in chronic heart failure and its therapeutic implications
    Cicoira, M
    Kalra, PR
    Anker, SD
    JOURNAL OF CARDIAC FAILURE, 2003, 9 (03) : 219 - 226
  • [7] PRECISION MEDICINE CLINICAL TRIAL OF GROWTH HORMONE DOSE ESCALATION FOR A PATIENT WITH A DOMINANT NEGATIVE GROWTH HORMONE RECEPTOR VARIANT
    Merchant, Nadia
    Boucher, Kimberly
    Dauber, Andrew
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 66 - 67
  • [8] Perspective on precision medicine in paediatric heart failure
    Fridman, Michael D.
    Mital, Seema
    CLINICAL SCIENCE, 2017, 131 (06) : 439 - 448
  • [9] Scenarios in precision medicine: proteomics in heart failure
    Gentile, Piero
    Palazzini, Matteo
    Garascia, Andrea
    Oliva, Fabrizio
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 : I111 - I113
  • [10] Precision Medicine for Heart Failure Back to the Future
    Feldman, Arthur M.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (10) : 1185 - 1188